Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... , ROCKVILLE, Md. , Jan. ... today that it has successfully completed a pre-clinical safety and ...  Results from this study are needed to support an Investigational ... protein particle based RSV (RSV-F) vaccine candidate into clinical development. ...
... ... syndicated radio host Dr. Ken Kronhaus to educate about the need for vascular screening in ... carotid arteries for potential causes of stroke, the abdominal aorta for aneurysms, and the legs ... ...
... new antimalarial drugs after discovering the normal function of ... protein, which causes resistance to the front-line drug chloroquine. ... the malarial chloroquine-resistance factor. The study examined transporter ... cell. The genes for these proteins are present in ...
Cached Biology Technology:NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 2NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 3NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 4NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 5Life Line Screening and Dr. Ken Kronhaus Work Together to Educate People About Vascular Screening 2Life Line Screening and Dr. Ken Kronhaus Work Together to Educate People About Vascular Screening 3Discovery provides new drug targets for malaria cure 2
(Date:4/22/2014)... Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered ... treat most neurodegenerative diseases that are characterized by ... diseases. These molecules are based on what the ... GAIM, which recognizes a characteristic common to many ... misfolded protein. This approach provides NeuroPhage with an ...
(Date:4/22/2014)... developing countries could be monitored from birth to ... a new technique piloted by a London-based university ... be visualised and tracked more quickly, more accurately ... near infra-red spectroscopy (fNIRS), compared to the behavioural ... , Professor Clare Elwell, Professor of Medical ...
(Date:4/21/2014)... HOUSTON, April 21, 2014 Performing brain research that ... advances, University of Houston (UH) junior Khanh (Kate) Nguyen ... science students. A double major in mathematics and physics, ... M. Goldwater Scholarship. , One of the most ... provides funding to sophomore and junior students majoring in ...
Breaking Biology News(10 mins):NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 2NeuroPhage discovers GAIM-changing molecules to combat Alzheimer's and related diseases 3First brain images of African infants enable research into cognitive effects of nutrition 2UH student named Goldwater Scholar, 2 more receive honorable mention 2UH student named Goldwater Scholar, 2 more receive honorable mention 3UH student named Goldwater Scholar, 2 more receive honorable mention 4
... and its consequent lack of access to care appears ... may partly explain the mortality disparity between African-Americans and ... Third AACR Conference on The Science of Cancer Health ... die within four years compared to white patients after ...
... African-American women with breast cancer living in Washington, D.C., ... of insurance type, socioeconomic status and cancer characteristics such ... an associate professor of epidemiology at The George Washington ... the impact of race and socioeconomic status on health ...
... ,Cincinnati, (OH) - The International Rett Syndrome Foundation ... $1.5M in research grants, bringing the 2010 total to ... that moves treatments for Rett syndrome a step closer ... private source of Rett syndrome research funding and with ...
Cached Biology News:Lack of private health insurance impacted cancer survival 2Racial differences in breast cancer treatment persist despite similar economics 2Research becomes a reality for Rett syndrome through new funding 2Research becomes a reality for Rett syndrome through new funding 3Research becomes a reality for Rett syndrome through new funding 4
Animal Origin Free...
IHC Detection Kit (Broad Spectrum AEC)....
...
... Modification Services ,,GenScript offers many ... and antibody fragmentation. Labeling antibodies with ... visualization and quantitation of the target ... preferable to use only the antigen-binding ...
Biology Products: